Literature DB >> 17601396

Aggressive statin therapy for acute coronary syndromes.

Tze Vun Liew1, Kausik K Ray.   

Abstract

Acute coronary syndromes (ACS) account for an enormous disease burden, especially in the Western world. Patients suffering acute coronary events are now understood to carry a very high risk of further coronary events and although improvements in conventional medical therapy over the past two decades have significantly reduced the risk, it remains high. Therapy with HMG CoA reductase inhibitors (statins) have now been well established for the primary and secondary prevention of stable coronary heart disease, but recently a substantial body of evidence has proven their efficacy in the treatment of ACS. This article examines this emerging evidence for the use of statins in ACS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17601396     DOI: 10.1007/bf02938378

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  35 in total

Review 1.  The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.

Authors:  Kausik K Ray; Christopher P Cannon
Journal:  J Am Coll Cardiol       Date:  2005-10-18       Impact factor: 24.094

2.  A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

Authors:  Stephen D Wiviott; James A de Lemos; Christopher P Cannon; Michael Blazing; Sabina A Murphy; Carolyn H McCabe; Robert Califf; Eugene Braunwald
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

3.  High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

Authors:  Anders G Olsson; Gregory G Schwartz; Michael Szarek; William J Sasiela; Michael D Ezekowitz; Peter Ganz; Michael F Oliver; David Waters; Andreas Zeiher
Journal:  Eur Heart J       Date:  2005-03-11       Impact factor: 29.983

4.  Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.

Authors:  L Wallentin; B Lagerqvist; S Husted; F Kontny; E Ståhle; E Swahn
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

5.  Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality.

Authors:  Gregg C Fonarow; R Scott Wright; Frederick A Spencer; Paul D Fredrick; Wei Dong; Nathan Every; William J French
Journal:  Am J Cardiol       Date:  2005-09-01       Impact factor: 2.778

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

8.  Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.

Authors:  H Buchwald; R L Varco; J R Boen; S E Williams; B J Hansen; C T Campos; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink; H S Sawin
Journal:  Arch Intern Med       Date:  1998-06-08

9.  Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.

Authors:  David D Waters; Gregory G Schwartz; Anders G Olsson; Andreas Zeiher; Michael F Oliver; Peter Ganz; Michael Ezekowitz; Bernard R Chaitman; Sally J Leslie; Theresa Stern
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

Review 10.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.